Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection

Haemophilia

Volumn 22, Issue 2, 2016, Pages 214-217

  Stedman, C A M ^a   Hyland, R H ^b   Ding, X ^b   Pang, P S ^b   Mchutchison, J G ^b   Gane, E J ^c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b GILEAD SCIENCES   (United States)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Antiviral; Haemophilia; Hepatitis C virus; Ledipasvir; Sofosbuvir

Indexed keywords

LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EXERTIONAL DYSPNEA; FATIGUE; FEMALE; HEADACHE; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INSOMNIA; INTERNATIONAL NORMALIZED RATIO; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; MULTICENTER STUDY; NAUSEA; PARTIAL THROMBOPLASTIN TIME; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RESTLESSNESS; UPPER RESPIRATORY TRACT INFECTION; VON WILLEBRAND DISEASE;

EID: 84960330845     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12791     Document Type: Article

References (9)

1. Zoulim F, Bailly F. New approaches to the management of hepatitis C in haemophilia in 2012. Haemophilia 2012; 18(Suppl. 4): 28-33.
2. Fransen van de Putte DE, Makris M, Fischer K, et al. Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders. J Hepatol 2014; 60: 39-45.
3. Franchini M, Mengoli C, Veneri D, Mazzi R, Lippi G, Cruciani M. Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis. J Antimicrob Chemother 2008; 61: 1191-200.
4. Harvoni (ledipasvir and sofosbuvir) tablets: US prescribing information. Foster City, CA: Gilead Sciences. Available at: http://www.gilead.com/~/media/Files/pdfs/medicines/liverdisease/harvoni/harvoni_pi.pdf. Accessed October 12, 2014.
5. Afdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98.
6. Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93.
7. Kowdley KV, Gordon SC, Reddy KR et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-88.
8. Gane EJ, Stedman CA, Hyland RH et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014; 146: 736-43.
9. Gane EJ, Stedman CA, Hyland RH et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44.